Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Metastatic renal cell cancer (mRCC) has a long history as a disease with poor prognosis and limited therapeutic options. Immunotherapy has been the mainstay of treatment since the 1980s, and there have been a number of largely phase II studies examining various schedules of interferon-alpha and interleukin-2 based treatments. With the development of molecular targeted drugs the armentarium against mRCC has significantly expanded and cytokine treatments should be only directed at those most likely to benefit with durable remissions and prolonged survival.
Parton
Marina
M
Department of Medicine, Royal Marsden Hospital, London, United Kingdom.
Gore
Martin
M
Eisen
Tim
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000276:immunology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2